These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 17145528)

  • 1. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial.
    Pow EH; Kwong DL; McMillan AS; Wong MC; Sham JS; Leung LH; Leung WK
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):981-91. PubMed ID: 17145528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
    Jabbari S; Kim HM; Feng M; Lin A; Tsien C; Elshaikh M; Terrel JE; Murdoch-Kinch C; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):725-31. PubMed ID: 16199308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function.
    Kwong DL; Pow EH; Sham JS; McMillan AS; Leung LH; Leung WK; Chua DT; Cheng AC; Wu PM; Au GK
    Cancer; 2004 Oct; 101(7):1584-93. PubMed ID: 15378492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.
    Lu TX; Mai WY; Teh BS; Zhao C; Han F; Huang Y; Deng XW; Lu LX; Huang SM; Zeng ZF; Lin CG; Lu HH; Chiu JK; Carpenter LS; Grant WH; Woo SY; Cui NJ; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):682-7. PubMed ID: 14967420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of quality of life of nasopharyngeal carcinoma patients with EORTC QLQ-C30 and H&N-35 modules.
    Cengiz M; Ozyar E; Esassolak M; Altun M; Akmansu M; Sen M; Uzel O; Yavuz A; Dalmaz G; Uzal C; Hiçsönmez A; Sarihan S; Kaplan B; Atasoy BM; Ulutin C; Abacioğlu U; Demiral AN; Hayran M
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1347-53. PubMed ID: 16169671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parotid gland-sparing 3-dimensional conformal radiotherapy results in less severe dry mouth in nasopharyngeal cancer patients: a dosimetric and clinical comparison with conventional radiotherapy.
    Jen YM; Shih R; Lin YS; Su WF; Ku CH; Chang CS; Shueng PW; Hwang JM; Liu DW; Chao HL; Lin HY; Chang LP; Shum WY; Lin CS
    Radiother Oncol; 2005 May; 75(2):204-9. PubMed ID: 15908027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.
    Blanco AI; Chao KS; El Naqa I; Franklin GE; Zakarian K; Vicic M; Deasy JO
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1055-69. PubMed ID: 15990009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
    Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
    Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function.
    Saarilahti K; Kouri M; Collan J; Hämäläinen T; Atula T; Joensuu H; Tenhunen M
    Radiother Oncol; 2005 Mar; 74(3):251-8. PubMed ID: 15763305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in quality of life of head-and-neck cancer patients following postoperative radiotherapy.
    Fang FM; Chien CY; Kuo SC; Chiu HC; Wang CJ
    Acta Oncol; 2004; 43(6):571-8. PubMed ID: 15370615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life in patients with oropharynx carcinomas: assessment after accelerated radiotherapy with or without chemotherapy versus radical surgery and postoperative radiotherapy.
    Allal AS; Nicoucar K; Mach N; Dulguerov P
    Head Neck; 2003 Oct; 25(10):833-9; discussion 839-40. PubMed ID: 12966507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using technology to decrease xerostomia for head and neck cancer patients treated with radiation therapy.
    Amosson CM; Teh BS; Mai WY; Woo SY; Chiu JK; Donovan DT; Parke R; Carpenter LS; Lu HH; Grant WH; Butler EB
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):71-9. PubMed ID: 12577249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy.
    Ravasco P; Monteiro-Grillo I; Marques Vidal P; Camilo ME
    Head Neck; 2005 Aug; 27(8):659-68. PubMed ID: 15920748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis.
    Duncan GG; Epstein JB; Tu D; El Sayed S; Bezjak A; Ottaway J; Pater J;
    Head Neck; 2005 May; 27(5):421-8. PubMed ID: 15782422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated radiotherapy: examples of its utility in head and neck cancer.
    Porceddu S; Hope G; Wills J; Cramb J; Rischin D; Corry J; Peters L
    Australas Radiol; 2004 Mar; 48(1):51-7. PubMed ID: 15027921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dosimetric evaluation for three dimensional conformal, conventional, and traditional radiotherapy plans for patients with early nasopharyngeal carcinoma].
    Luo W; Deng XW; Lu TX
    Ai Zheng; 2004 May; 23(5):605-8. PubMed ID: 15142465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study.
    Lin A; Kim HM; Terrell JE; Dawson LA; Ship JA; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):61-70. PubMed ID: 12909216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.